Incorrect Reference
In the original article, there is a mistake in the references cited in the text. From reference 105 onwards, the number does not correspond to the correct citation. The corrected references appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
TurnerJR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. (2009) 9:799–809. 10.1038/nri2653
2.
HelanderHFFändriksL. Surface area of the digestive tract-revisited. Scand J Gastroenterol. (2014) 49:681–9. 10.3109/00365521.2014.898326
3.
CamilleriM. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. (2019) 68:1516–26. 10.1136/gutjnl-2019-318427
4.
YenTHWrightNA. The gastrointestinal tract stem cell niche. Stem Cell Rev. (2006) 2:203–12. 10.1007/s12015-006-0048-1
5.
Von MoltkeJJiMLiangHELocksleyRM. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature. (2016) 529:221–5. 10.1038/nature16161
6.
BischoffSCBarbaraGBuurmanWOckhuizenTSchulzkeJDSerinoMet al. Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterol. (2014) 14:189. 10.1186/s12876-014-0189-7
7.
Salvo-RomeroEAlonso-CotonerCPardo-CamachoCCasado-BedmarMVicarioM. The intestinal barrier function and its involvement in digestive disease. Rev Esp Enfermedades Dig. (2015) 107:686–96. 10.17235/reed.2015.3846/2015
8.
MeddingsJ. The significance of the gut barrier in disease. Gut. (2008) 57:438–40. 10.1136/gut.2007.143172
9.
HanssonGC. Mucus and mucins in diseases of the intestinal and respiratory tracts. J Intern Med. (2019) 285:479–90. 10.1111/joim.12910
10.
GilloisKLévêqueMThéodorouVRobertHMercier-BoninM. Mucus: an underestimated gut target for environmental pollutants and food additives. Microorganisms. (2018) 6:53. 10.3390/microorganisms6020053
11.
JohanssonMEVHanssonGC. Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol. (2016) 16:639–49. 10.1038/nri.2016.88
12.
ConeRA. Barrier properties of mucus. Adv Drug Deliv Rev. (2009) 61:75–85. 10.1016/j.addr.2008.09.008
13.
KönigJWellsJCaniPDGarcía-RódenasCLMacDonaldTMercenierAet al. Human intestinal barrier function in health and disease. Clin Transl Gastroenterol. (2016) 7:e196. 10.1038/ctg.2016.54
14.
KimYSHoSB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. (2010) 12:319–30. 10.1007/s11894-010-0131-2
15.
HanssonGC. Mucins and the Microbiome. Annu Rev Biochem. (2020) 89:769–93. 10.1146/annurev-biochem-011520-105053
16.
BansilRTurnerBS. The biology of mucus: composition, synthesis and organization. Adv Drug Deliv Rev. (2018) 124:3–15. 10.1016/j.addr.2017.09.023
17.
LAMONTJT. Mucus: the front line of intestinal mucosal defense. Ann N Y Acad Sci. (1992) 664:190–201. 10.1111/j.1749-6632.1992.tb39760.x
18.
KimJJKhanWI. Goblet cells and mucins: role in innate defense in enteric infections. Pathogens. (2013) 2:55–70. 10.3390/pathogens2010055
19.
StrugnellRAWijburgOLC. The role of secretory antibodies in infection immunity. Nat Rev Microbiol. (2010) 8:656–67. 10.1038/nrmicro2384
20.
HuusKEPetersenCFinlayBB. Diversity and dynamism of IgA–microbiota interactions. Nat Rev Immunol. (2021) 21:514–25. 10.1038/s41577-021-00506-1
21.
PelaseyedTHanssonGC. Membrane mucins of the intestine at a glance. J Cell Sci. (2020) 133:jcs240929. 10.1242/JCS.240929
22.
Etienne-MesminLChassaingBDesvauxMDe PaepeKGresseRSauvaitreTet al. Experimental models to study intestinal microbes–mucus interactions in health and disease. FEMS Microbiol Rev. (2019) 43:457–89. 10.1093/femsre/fuz013
23.
PelaseyedTBergströmJHGustafssonJKErmundABirchenoughGMHSchütteAet al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev. (2014) 260:8–20. 10.1111/imr.12182
24.
PabstOMowatAM. Oral tolerance to food protein. Mucosal Immunol. (2012) 5:232–9. 10.1038/mi.2012.4
25.
ShanMGentileMYeiserJRWallandACBornsteinVUChenKet al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. (2013) 342:447–53. 10.1126/science.1237910
26.
ErmundAGustafssonJKHanssonGCKeitaÅ V. Mucus properties and goblet cell quantification in mouse, rat and human ileal Peyer's patches. PLoS ONE. (2013) 8:e83688. 10.1371/journal.pone.0083688
27.
JohanssonMEVHolmén LarssonJMHanssonGC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA. (2011) 108:4659–65. 10.1073/pnas.1006451107
28.
AtumaCStrugalaVAllenAHolmL. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. (2001) 280:G922–9. 10.1152/ajpgi.2001.280.5.g922
29.
ErmundASchütteAJohanssonMEVGustafssonJKHanssonGC. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer's patches. Am J Physiol Gastrointest Liver Physiol. (2013) 305:G341–7. 10.1152/ajpgi.00046.2013
30.
BirchenoughGMHJohanssonMEVGustafssonJKBergströmJHHanssonGC. New developments in goblet cell mucus secretion and function. Mucosal Immunol. (2015) 8:712–9. 10.1038/mi.2015.32
31.
OuelletteAJ. Paneth cells and innate mucosal immunity. Curr Opin Gastroenterol. (2010) 26:547–53. 10.1097/MOG.0b013e32833dccde
32.
HeazlewoodCKCookMCEriRPriceGRTauroSBTaupinDet al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med. (2008) 5:54. 10.1371/journal.pmed.0050054
33.
RennerMBergmannGKrebsIEndCLyerSHilbergFet al. DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease. Gastroenterology. (2007) 133:1499–509. 10.1053/j.gastro.2007.08.007
34.
HooperLVMacPhersonAJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. (2010) 10:159–69. 10.1038/nri2710
35.
Meyer-HoffertUHornefMWHenriques-NormarkBAxelssonLGMidtvedtTPütsepKet al. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut. (2008) 57:764–71. 10.1136/gut.2007.141481
36.
Van Der WaaijLAHarmsenHJMMadjipourMKroeseFGMZwiersMVan DullemenHMet al. Bacterial population analysis of human colon and terminal ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. Inflamm Bowel Dis. (2005) 11:865–71. 10.1097/01.mib.0000179212.80778.d3
37.
JohanssonMEVPhillipsonMPeterssonJVelcichAHolmLHanssonGC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA. (2008) 105:15064–9. 10.1073/pnas.0803124105
38.
JohanssonMEVSjövallHHanssonGC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. (2013) 10:352–61. 10.1038/nrgastro.2013.35
39.
LiHLimenitakisJPFuhrerTGeukingMBLawsonMAWyssMet al. The outer mucus layer hosts a distinct intestinal microbial niche. Nat Commun. (2015) 6:8292. 10.1038/ncomms9292
40.
KamphuisJBJMercier-BoninMEutamèneHTheodorouV. Mucus organisation is shaped by colonic content; a new view. Sci Rep. (2017) 7:8527. 10.1038/s41598-017-08938-3
41.
HoskinsLCBouldingET. Mucin degradation in human colon ecosystems. J Clin Invest. (1981) 67:163–72. 10.1172/jci110009
42.
PngCWLindénSKGilshenanKSZoetendalEGMcSweeneyCSSlyLIet al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. (2010) 105:2420–8. 10.1038/ajg.2010.281
43.
DesaiMSSeekatzAMKoropatkinNMKamadaNHickeyCAWolterMet al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell. (2016) 167:1339–53.e21. 10.1016/j.cell.2016.10.043
44.
JohanssonMEVJakobssonHEHolmén-LarssonJSchütteAErmundARodríguez-PiñeiroAMet al. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe. (2015) 18:582–92. 10.1016/j.chom.2015.10.007
45.
SchroederBO. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota. Gastroenterol Rep. (2019) 7:3–12. 10.1093/gastro/goy052
46.
FuJWeiBWenTJohanssonMEVLiuXBradfordEet al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest. (2011) 121:1657–66. 10.1172/JCI45538
47.
LarssonJMHKarlssonHCrespoJGJohanssonMEVEklundLSjövallHet al. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis. (2011) 17:2299–307. 10.1002/ibd.21625
48.
JohanssonMEVGustafssonJKHolmen-LarssonJJabbarKSXiaLXuHet al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. (2014) 63:281–91. 10.1136/gutjnl-2012-303207
49.
StrugalaVDettmarPWPearsonJP. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int J Clin Pract. (2008) 62:762–9. 10.1111/j.1742-1241.2007.01665.x
50.
PullanRDThomasGAORhodesMNewcombeRGWilliamsGTAllenAet al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut. (1994) 35:353–9. 10.1136/gut.35.3.353
51.
BuisineMPDesreumauxPLeteurtreECopinMCColombelJFPorchetNet al. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut. (2001) 49:544–51. 10.1136/gut.49.4.544
52.
BuisineMPDesreumauxPDebailleulVGambiezLGeboesKEctorsNet al. Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis. (1999) 5:24–32. 10.1097/00054725-199902000-00004
53.
NakamoriSOtaDMClearyKRShirotaniKIrimuraT. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology. (1994) 106:353–61. 10.1016/0016-5085(94)90592-4
54.
AjiokaYAllisonLJJassJR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol. (1996) 49:560–4. 10.1136/jcp.49.7.560
55.
McGuckinMALindénSKSuttonPFlorinTH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol. (2011) 9:265–78. 10.1038/nrmicro2538
56.
DharmaniPSrivastavaVKissoon-SinghVChadeeK. Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun. (2009) 1:123–35. 10.1159/000163037
57.
HayashiFSmithKDOzinskyAHawnTRYiECGoodlettDRet al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. (2001) 410:1099–103. 10.1038/35074106
58.
BirchenoughGMHNystromEELJohanssonMEVHanssonGC. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. Science. (2016) 352:1535–42. 10.1126/science.aaf7419
59.
WangSAhmadiSNagpalRJainSMishraSPKavanaghKet al. Lipoteichoic acid from the cell wall of a heat killed Lactobacillus paracasei D3-5 ameliorates aging-related leaky gut, inflammation and improves physical and cognitive functions: from C. elegans to mice. GeroScience. (2020) 42:333–52. 10.1007/s11357-019-00137-4
60.
LeeKDGukSMChaiJY. Toll-like receptor 2 and Muc2 expression on human intestinal epithelial cells by gymnophalloides seoi adult antigen. J Parasitol. (2010) 96:58–66. 10.1645/GE-2195.1
61.
KamdarKJohnsonAMFChacDMyersKKulurVTruevillianKet al. Innate recognition of the microbiota by TLR1 promotes epithelial homeostasis and prevents chronic inflammation. J Immunol. (2018) 201:230–42. 10.4049/jimmunol.1701216
62.
AndersonJMVan ItallieCM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. (2009) 1:a002584. 10.1101/cshperspect.a002584
63.
FuruseMFujitaKHiiragiTFujimotoKTsukitaS. Claudin-1 and−2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. (1998) 141:1539–50. 10.1083/jcb.141.7.1539
64.
FuruseMHiraseTItohMNagafuchiAYonemuraSTsukitaSet al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. (1993) 123:1777–88. 10.1083/jcb.123.6.1777
65.
Martìn-PaduraILostaglioSSchneemannMWilliamsLRomanoMFruscellaPet al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. (1998) 142:117–27. 10.1083/jcb.142.1.117
66.
IkenouchiJUmedaKTsukitaSFuruseMTsukitaS. Requirement of ZO-1 for the formation of belt-like adherens junctions during epithelial cell polarization. J Cell Biol. (2007) 176:779–86. 10.1083/jcb.200612080
67.
GünzelDFrommM. Claudins and other tight junction proteins. Compr Physiol. (2012) 2:1819–52. 10.1002/cphy.c110045
68.
GünzelDYuASL. Claudins and the modulation of tight junction permeability. Physiol Rev. (2013) 93:525–69. 10.1152/physrev.00019.2012
69.
SuzukiT. Regulation of the intestinal barrier by nutrients: the role of tight junctions. Anim Sci J. (2020) 91:e13357. 10.1111/asj.13357
70.
CongXKongW. Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease. Cell Signal. (2020) 66:109485. 10.1016/j.cellsig.2019.109485
71.
ShenLWeberCRRaleighDRYuDTurnerJR. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. (2011) 73:283–309. 10.1146/annurev-physiol-012110-142150
72.
Van ItallieCMAndersonJM. Claudins and epithelial paracellular transport. Annu Rev Physiol. (2006) 68:403–29. 10.1146/annurev.physiol.68.040104.131404
73.
HellerFFlorianPBojarskiCRichterJChristMHillenbrandBet al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. (2005) 129:550–64. 10.1016/j.gastro.2005.05.002
74.
IvanovAINusratAParkosCA. The epithelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption. Novartis Found Symp. (2004) 263:115–24. 10.1002/0470090480.ch9
75.
KucharzikTWalshS V.ChenJParkosCANusratA. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol. (2001) 159:2001–9. 10.1016/S0002-9440(10)63051-9
76.
PizzutiDSenzoloMBudaAChiarelliSGiacomelliLMazzonEet al. In vitro model for IgE mediated food allergy. Scand J Gastroenterol. (2011) 46:177–87. 10.3109/00365521.2010.525716
77.
AssimakopoulosSFTsamandasACTsiaoussisGIKaratzaETriantosCVagianosCEet al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. (2012) 42:439–46. 10.1111/j.1365-2362.2011.02609.x
78.
Bertiaux-VandaëleNYoumbaSBBelmonteLLecleireSAntoniettiMGourcerolGet al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol. (2011) 106:2165–73. 10.1038/ajg.2011.257
79.
RahnerCMiticLLAndersonJM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology. (2001) 120:411–22. 10.1053/gast.2001.21736
80.
ReyesJLLamasMMartinDNamoradoMDCIslasSLunaJet al. The renal segmental distribution of claudins changes with development. Kidney Int. (2002) 62:476–87. 10.1046/j.1523-1755.2002.00479.x
81.
WolburgHWolburg-BuchholzKLiebnerSEngelhardtB. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci Lett. (2001) 307:77–80. 10.1016/S0304-3940(01)01927-9
82.
ZhuYBrännströmMJansonPOSundfeldtK. Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer. (2006) 118:1884–91. 10.1002/ijc.21506
83.
OshimaTMiwaHJohT. Changes in the expression of claudins in active ulcerative colitis. J Gastroenterol Hepatol. (2008) 23:3–7. 10.1111/j.1440-1746.2008.05405.x
84.
NagySzakál DGyorffyHAratóACsehÁMolnárKPappMet al. Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease. Virchows Arch. (2010) 456:245–50. 10.1007/s00428-009-0879-7
85.
MartínezCLoboBPigrauMRamosLGonzález-CastroAMAlonsoCet al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. (2013) 62:1160–8. 10.1136/gutjnl-2012-302093
86.
ZeissigSBürgelNGünzelDRichterJMankertzJWahnschaffeUet al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. (2007) 56:61–72. 10.1136/gut.2006.094375
87.
LaurilaJJKarttunenTKoivukangasVLaurilaPASyrjäläHSaarnioJet al. Tight junction proteins in gallbladder epithelium: different expression in acute acalculous and calculous cholecystitis. J Histochem Cytochem. (2007) 55:567–73. 10.1369/jhc.6A7155.2007
88.
WolburgHWolburg-BuchholzKKrausJRascher-EggsteinGLiebnerSHammSet al. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. (2003) 105:586–92. 10.1007/s00401-003-0688-z
89.
Kiuchi-SaishinYGotohSFuruseMTakasugaATanoYTsukitaS. Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. J Am Soc Nephrol. (2002) 13:875–86. 10.1681/asn.v134875
90.
MennigenRNolteKRijckenEUtechMLoefflerBSenningerNet al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. (2009) 296:G1140–9. 10.1152/ajpgi.90534.2008
91.
OshimaTMiwaH. Gastrointestinal mucosal barrier function and diseases. J Gastroenterol. (2016) 51:768–78. 10.1007/s00535-016-1207-z
92.
SaponeALammersKMCasolaroVCammarotaMGiulianoMTDe RosaMet al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: Celiac disease and gluten sensitivity. BMC Med. (2011) 9:23. 10.1186/1741-7015-9-23
93.
MoritaKSasakiHFuruseMTsukitaS. Endothelial claudin: Claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol. (1999) 147:185–94. 10.1083/jcb.147.1.185
94.
NittaTHataMGotohSSeoYSasakiHHashimotoNet al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. (2003) 161:653–60. 10.1083/jcb.200302070
95.
AmashehSSchmidtTMahnMFlorianPMankertzJTavalaliSet al. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. Cell Tissue Res. (2005) 321:89–96. 10.1007/s00441-005-1101-0
96.
SchumannMGünzelDBuergelNRichterJFTroegerHMayCet al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut. (2012) 61:220–8. 10.1136/gutjnl-2011-300123
97.
FujitaHChibaHYokozakiHSakaiNSugimotoKWadaTet al. Differential expression and subcellular localization of claudin-7,−8,−12,−13, and−15 along the mouse intestine. J Histochem Cytochem. (2006) 54:933–44. 10.1369/jhc.6A6944.2006
98.
GoMKojimaTTakanoKIMurataMIchimiyaSTsubotaHet al. Expression and function of tight junctions in the crypt epithelium of human palatine tonsils. J Histochem Cytochem. (2004) 52:1627–38. 10.1369/jhc.4A6339.2004
99.
LiWYHueyCLYuAS. Expression of claudin-7 and−8 along the mouse nephron. Am J Physiol Renal Physiol. (2004) 286:F1063–71.10.1152/ajprenal.00384.2003
100.
TurksenKTroyTC. Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev Dyn. (2001) 222:292–300. 10.1002/dvdy.1174
101.
LamerisALHuybersSKaukinenKMäkeläTHBindelsRJHoenderopJGet al. Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease. Scand J Gastroenterol. (2013) 48:58–69. 10.3109/00365521.2012.741616
102.
NiimiTNagashimaKWardJMMinooPZimonjicDBPopescuNCet al. claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. (2001) 21:7380–90. 10.1128/mcb.21.21.7380-7390.2001
103.
LinaresGRBrommageRPowellDRXingWChenSTAlshboolFZet al. Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation. J Bone Miner Res. (2012) 27:1553–65. 10.1002/jbmr.1600
104.
SanadaYOueNMitaniYYoshidaKNakayamaHYasuiW. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. (2006) 208:633–42. 10.1002/path.1922
105.
WongV. Phosphorylation of occludin correlates with occludin localization and function at the tight junction. Am J Physiol Cell Physiol. (1997) 273:C1859–67. 10.1152/ajpcell.1997.273.6.c1859
106.
UmedaKIkenouchiJKatahira-TayamaSFuruseKSasakiHNakayamaMet al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell. (2006) 126:741–54. 10.1016/j.cell.2006.06.043
107.
González-MariscalLQuirósMDíaz-CoránguezM. ZO proteins and redox-dependent processes. Antioxidants Redox Signal. (2011) 15:1235–53. 10.1089/ars.2011.3913
108.
JesaitisLAGoodenoughDA. Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the Drosophila discs-large tumor suppressor protein. J Cell Biol. (1994) 124:949–61. 10.1083/jcb.124.6.949
109.
FanningASJamesonBJJesaitisLAAndersonJM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem. (1998) 273:29745–53. 10.1074/jbc.273.45.29745
110.
ItohMMoritaKTsukitaS. Characterization of ZO-2 as a MAGUK family member associated with tight as well as adherens junctions with a binding affinity to occludin and α catenin. J Biol Chem. (1999) 274:5981–6. 10.1074/jbc.274.9.5981
111.
FanningASMaTYAndersonJM. Isolation and functional characterization of the actin binding region in the tight junction protein ZO-1. FASEB J. (2002) 16:1835–7. 10.1096/fj.02-0121fje
112.
MandellKJParkosCA. The JAM family of proteins. Adv Drug Deliv Rev. (2005) 57:857–67. 10.1016/j.addr.2005.01.005
113.
EbnetK. Junctional adhesion molecules (JAMs): cell adhesion receptors with pleiotropic functions in cell physiology and development. Physiol Rev. (2017) 97:1529–54. 10.1152/physrev.00004.2017
114.
Van ItallieCMAndersonJM. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol. (2014) 36:157–65. 10.1016/j.semcdb.2014.08.011
115.
LaukoetterMGNavaPLeeWYSeversonEACapaldoCTBabbinBAet al. JAM-A regulates permeability and inflammation in the intestine in vivo. J Exp Med. (2007) 204:3067–76. 10.1084/jem.20071416
116.
SeversonEALeeWYCapaldoCTNusratAParkosCA. Junctional adhesion molecule a interacts with afadin and PDZ-GEF2 to activate raplA, regulate j31 integrin levels, and enhance cell migration. Mol Biol Cell. (2009) 20:1916–25. 10.1091/mbc.E08-10-1014
117.
NavaPCapaldoCTKochSKolegraffKRankinCRFarkasAEet al. JAM-A regulates epithelial proliferation through Akt/β-catenin signalling. EMBO Rep. (2011) 12:314–20. 10.1038/embor.2011.16
118.
MonteiroACSumaginRRankinCRLeoniGMinaMJReiterDMet al. JAM-A associates with ZO-2, afadin, and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function. Mol Biol Cell. (2013) 24:2849–60. 10.1091/mbc.E13-06-0298
119.
HollanderDVadheimCMBrettholzEPetersenGMDelahuntyTRotterJI. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic factor. Ann Intern Med. (1986) 105:883–5. 10.7326/0003-4819-105-6-883
120.
MartínezCVicarioMRamosLLoboBMosqueraJLAlonsoCet al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol. (2012) 107:736–46. 10.1038/ajg.2011.472
121.
Wilcz-VillegaEMccleanSO'SullivanM. Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS. Neurogastroenterol Motil. (2014) 26:316–25. 10.1111/nmo.12262
122.
DragoSEl AsmarRDi PierroMClementeMGTripathiASaponeAet al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. (2006) 41:408–19. 10.1080/00365520500235334
123.
VetranoSRescignoMRosaria CeraMCorrealeCRumioCDoniAet al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory Bowel disease. Gastroenterology. (2008) 135:173–84. 10.1053/j.gastro.2008.04.002
124.
Wilcz-VillegaEMMcCleanSO'SullivanMA. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. Am J Gastroenterol. (2013) 108:1140–51. 10.1038/ajg.2013.92
125.
CordenonsiMD'AtriFHammarEParryDADKendrick-JonesJShoreDet al. Cingulin contains globular and coiled-coil domains and interacts with ZO-1, ZO-2, ZO-3, and myosin. J Cell Biol. (1999) 147:1569–81. 10.1083/jcb.147.7.1569
126.
CitiSPaschoudSPulimenoPTimolatiFDe RobertisFJondLet al. The tight junction protein cingulin regulates gene expression and rhoA signaling. Ann N Y Acad Sci. (2009) 1165:88–98. 10.1111/j.1749-6632.2009.04053.x
127.
SuarezCKovarDR. Internetwork competition for monomers governs actin cytoskeleton organization. Nat Rev Mol Cell Biol. (2016) 17:799–810. 10.1038/nrm.2016.106
128.
KimSCoulombePA. Emerging role for the cytoskeleton as an organizer and regulator of translation. Nat Rev Mol Cell Biol. (2010) 11:75–81. 10.1038/nrm2818
129.
Al-SadiRMMaTY. IL-1β Causes an Increase in Intestinal Epithelial Tight Junction Permeability. J Immunol. (2007) 178:4641–9. 10.4049/jimmunol.178.7.4641
130.
SchwayerCShamipourSPranjic-FerschaKSchauerABaldaMTadaMet al. Mechanosensation of tight junctions depends on ZO-1 phase separation and flow. Cell. (2019) 179:937–52.e18. 10.1016/j.cell.2019.10.006
131.
HolthöferBWindofferRTroyanovskySLeubeRE. Structure and function of desmosomes. Int Rev Cytol. (2007) 264:65–163. 10.1016/S0074-7696(07)64003-0
132.
HartsockANelsonWJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta Biomembr. (2008) 1778:660–9. 10.1016/j.bbamem.2007.07.012
133.
ShapiroLWeisWI. Structure and biochemistry of cadherins and catenins. Cold Spring Harb Perspect Biol. (2009) 1:a003053. 10.1101/cshperspect.a003053
134.
IvanovAINaydenovNG. Dynamics and regulation of epithelial adherens junctions. Recent discoveries and controversies. Int Rev Cell Mol Biol. (2013) 303:27–99. 10.1016/B978-0-12-407697-6.00002-7
135.
TakeichiM. Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling. Nat Rev Mol Cell Biol. (2014) 15:397–410. 10.1038/nrm3802
136.
NekrasovaOEAmargoEVSmithWOChenJKreitzerGEGreenKJ. Desmosomal cadherins utilize distinct kinesins for assembly into desmosomes. J Cell Biol. (2011) 195:1185–203. 10.1083/jcb.201106057
137.
HatzfeldMKeilRMaginTM. Desmosomes and intermediate filaments: their consequences for tissue mechanics. Cold Spring Harb Perspect Biol. (2017) 9:a029157. 10.1101/cshperspect.a029157
138.
TripathiALammersKMGoldblumSShea-DonohueTNetzel-ArnettSBuzzaMSet al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. (2009) 106:16799–804. 10.1073/pnas.0906773106
139.
LammersKMLuRBrownleyJLuBGerardCThomasKet al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. (2008) 135:194–204.e3. 10.1053/j.gastro.2008.03.023
140.
SaponeADe MagistrisLPietzakMClementeMGTripathiACuccaFet al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. (2006) 55:1443–9. 10.2337/db05-1593
141.
BarbaroMRCremonCWronaDFuschiDMarascoGStanghelliniVet al. Non-celiac gluten sensitivity in the context of functional gastrointestinal disorders. Nutrients. (2020) 12:1–21. 10.3390/nu12123735
142.
FasanoA. Zonulin measurement conundrum: add confusion to confusion does not lead to clarity. Gut. (2020) 70:2007–8. 10.1136/gutjnl-2020-323367
143.
MisraA. Challenges in delivery of therapeutic genomics and proteomics.Amsterdam: Elsevier Inc. (2011). 10.1016/C2010-0-65663-X
144.
SuganoKKansyMArturssonPAvdeefABendelsSDiLet al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov. (2010) 9:597–614. 10.1038/nrd3187
145.
WangYDeMazumderDHillJA. Ionic fluxes and genesis of the cardiac action potential. Muscle. (2012) 1:67–85. 10.1016/B978-0-12-381510-1.00007-7
146.
HorisbergerJDChraïbiA. Epithelial sodium channel: a ligand-gated channel?Nephron Physiol. (2004) 96:37–41. 10.1159/000076406
147.
MukherjeeBSatapathyBSBhattacharyaSChakrabortyRMishraVP. Chapter 19 - Pharmacokinetic and pharmacodynamic modulations of therapeutically active constituents from orally administered nanocarriers along with a glimpse of their advantages and limitations. In: Grumezescu AM, editor. Nano- and Microscale Drug Delivery Systems. Elsevier. (2017). p. 357–75. 10.1016/B978-0-323-52727-9.00019-4
148.
GoldsteinJLAndersonRGWBrownMS. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature. (1979) 279:679–85. 10.1038/279679a0
149.
Garcia-CastilloMDChinnapenDJFLencerWI. Membrane transport across polarized epithelia. Cold Spring Harb Perspect Biol. (2017) 9:a027912. 10.1101/cshperspect.a027912
150.
SandvigKKavaliauskieneSSkotlandT. Clathrin-independent endocytosis: an increasing degree of complexity. Histochem Cell Biol. (2018) 150:107–18. 10.1007/s00418-018-1678-5
151.
TumaPLHubbardAL. Transcytosis: crossing cellular barriers. Physiol Rev. (2003) 83:871–932. 10.1152/physrev.00001.2003
152.
MesteckyJRussellMWElsonCO. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut. (1999) 44:2–5. 10.1136/gut.44.1.2
153.
KadaouiKACorthésyB. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol. (2007) 179:7751–7. 10.4049/jimmunol.179.11.7751
154.
BoullierSTanguyMKadaouiKACaubetCSansonettiPCorthésyBet al. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J Immunol. (2009) 183:5879–85. 10.4049/jimmunol.0901838
155.
ReyJGarinNSpertiniFCorthésyB. Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells. J Immunol. (2004) 172:3026–33. 10.4049/jimmunol.172.5.3026
156.
Matysiak-BudnikTMouraICArcos-FajardoMLebretonCMénardSCandalhCet al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med. (2008) 205:143–54. 10.1084/jem.20071204
157.
BevilacquaCMontagnacGBenmerahACandalhCBrousseNCerf-BensussanNet al. Food allergens are protected from degradation during CD23-mediated transepithelial transport. Int Arch Allergy Immunol. (2004) 205:143–54. 10.1159/000080653
158.
KaiserlianDLachauxAGrosjeanIGraberPBonnefoyJY. Intestinal epithelial cells express the CD23/FcεRII molecule: enhanced expression in enteropathies. Immunology. (1993) 80:90–5.
159.
MontagnacGYuLCHBevilacquaCHeymanMConradDHPerdueMHet al. Differential role for CD23 splice forms in apical to basolateral transcytosis of IgE/allergen complexes. Traffic. (2005) 6:230–42. 10.1111/j.1600-0854.2005.00262.x
160.
MontagnacGMollà-HermanABouchetJYuLCHConradDHPerdueMHet al. Intracellular trafficking of CD23: differential regulation in humans and mice by both extracellular and intracellular exons. J Immunol. (2005) 174:5562–72. 10.4049/jimmunol.174.9.5562
161.
NealMDLeaphartCLevyRPrinceJBilliarTRWatkinsSet al. Enterocyte TLR4 Mediates Phagocytosis and Translocation of Bacteria Across the Intestinal Barrier. J Immunol. (2006) 176:3070–9. 10.4049/jimmunol.176.5.3070
162.
ConnerSDSchmidSL. Regulated portals of entry into the cell. Nature. (2003) 422:37–44. 10.1038/nature01451
163.
GüntherJSeyfertHM. The first line of defence: insights into mechanisms and relevance of phagocytosis in epithelial cells. Semin Immunopathol. (2018) 40:555–65. 10.1007/s00281-018-0701-1
164.
HommelgaardAMRoepstorffKVilhardtFTorgersenMLSandvigKvan DeursB. Caveolae: stable membrane domains with a potential for internalization. Traffic. (2005) 6:720–4. 10.1111/j.1600-0854.2005.00314.x
165.
MaloyKJPowrieF. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. (2011) 474:298–306. 10.1038/nature10208
166.
KhorBGardetAXavierRJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. (2011) 474:307–17. 10.1038/nature10209
167.
SuzukiT. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. (2013) 70:631–59. 10.1007/s00018-012-1070-x
168.
BerkesJViswanathanVKSavkovicSDHechtG. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut. (2003) 52:439–51. 10.1136/gut.52.3.439
169.
BäckhedFLeyRESonnenburgJLPetersonDAGordonJI. Host-bacterial mutualism in the human intestine. Science. (2005) 307:1915–20. 10.1126/science.1104816
170.
HooperL V.LittmanDRMacphersonAJ. Interactions between the microbiota and the immune system. Science. (2012) 336:1268–73. 10.1126/science.1223490
171.
KayamaHOkumuraRTakedaK. Interaction between the microbiota, epithelia, and immune cells in the intestine. Annu Rev Immunol. (2020) 38:23–48. 10.1146/annurev-immunol-070119-115104
172.
SonnenburgEDSmitsSATikhonovMHigginbottomSKWingreenNSSonnenburgJL. Diet-induced extinctions in the gut microbiota compound over generations. Nature. (2016) 529:212–5. 10.1038/nature16504
173.
LeBlancJGMilaniCde GioriGSSesmaFvan SinderenDVenturaM. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. (2013) 24:160–8. 10.1016/j.copbio.2012.08.005
174.
BaümlerAJSperandioV. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. (2016) 535:85–93. 10.1038/nature18849
175.
BuffieCGPamerEG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. (2013) 13:790–801. 10.1038/nri3535
176.
GensollenTIyerSSKasperDLBlumbergRS. How colonization by microbiota in early life shapes the immune system. Science. (2016) 352:539–44. 10.1126/science.aad9378
177.
ThaissCAZmoraNLevyMElinavE. The microbiome and innate immunity. Nature. (2016) 535:65–74. 10.1038/nature18847
178.
StecherBHardtWD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol. (2011) 14:82–91. 10.1016/j.mib.2010.10.003
179.
KeeneyKMFinlayBB. Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut. Curr Opin Microbiol. (2011) 14:92–8. 10.1016/j.mib.2010.12.012
180.
LitvakYByndlossMXBäumlerAJ. Colonocyte metabolism shapes the gut microbiota. Science. (2018) 362:eaat9076. 10.1126/science.aat9076
181.
van ThielIAMde JongeWJChiuIMvan den WijngaardRM. Microbiota-neuroimmune cross talk in stress-induced visceral hypersensitivity of the bowel. Am J Physiol Gastrointest Liver Physiol. (2020) 318:G1034–41. 10.1152/ajpgi.00196.2019
182.
ChowdhurySRKingDEWillingBPBandMRBeeverJELaneABet al. Transcriptome profiling of the small intestinal epithelium in germfree versus conventional piglets. BMC Genomics. (2007) 8:215. 10.1186/1471-2164-8-215
183.
Burger-van PaassenNVincentAPuimanPJvan der SluisMBoumaJBoehmGet al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J. (2009) 420:211–9. 10.1042/BJ20082222
184.
KimMHKangSGParkJHYanagisawaMKimCH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. (2013) 145:396–406.e1-10. 10.1053/j.gastro.2013.04.056
185.
SinghNGuravASivaprakasamSBradyEPadiaRShiHet al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. (2014) 40:128–39. 10.1016/j.immuni.2013.12.007
186.
GhoshSWhitleyCSHaribabuBJalaVR. Regulation of intestinal barrier function by microbial. Cell Mol Gastroenterol Hepatol. (2021) 11:1463–82. 10.1016/j.jcmgh.2021.02.007
187.
AbreuMT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. (2010) 10:131–43. 10.1038/nri2707
188.
BurgueñoJFAbreuMT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. (2020) 17:263–78. 10.1038/s41575-019-0261-4
189.
Allam-NdoulBCastonguay-ParadisSVeilleuxA. Gut microbiota and intestinal trans-epithelial permeability. Int J Mol Sci. (2020) 21:1–14. 10.3390/ijms21176402
190.
HayesCLDongJGalipeauHJJuryJMcCarvilleJHuangXet al. Commensal microbiota induces colonic barrier structure and functions that contribute to homeostasis. Sci Rep. (2018) 8:14184. 10.1038/s41598-018-32366-6
191.
HooperL V.WongMHThelinAHanssonLFalkPGGordonJI. Molecular analysis of commensal host-microbial relationships in the intestine. Science. (2001) 291:881–4. 10.1126/science.291.5505.881
192.
UkenaSNSinghADringenbergUEngelhardtRSeidlerUHansenWet al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE. (2007) 2:e1308. 10.1371/journal.pone.0001308
193.
BarbaroMRFuschiDCremonCCarapelleMDinoPMarcelliniMMet al. Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. Neurogastroenterol Motil. (2018) 30:e13388. 10.1111/nmo.13388
194.
Johnson-HenryKCDonatoKAShen-TuGGordanpourMShermanPM. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun. (2008) 76:1340–8. 10.1128/IAI.00778-07
195.
YuQYuanLDengJYangQ. Lactobacillus protects the integrity of intestinal epithelial barrier damaged by pathogenic bacteria. Front Cell Infect Microbiol. (2015) 5:26. 10.3389/fcimb.2015.00026
196.
ZareieMRiffJDonatoKMcKayDMPerdueMHSoderholmJDet al. Novel effects of the prototype translocating Escherichia coli, strain C25 on intestinal epithelial structure and barrier function. Cell Microbiol. (2005) 7:1782–97. 10.1111/j.1462-5822.2005.00595.x
197.
BarbaraGFeinle-BissetCGhoshalUCSantosJVannerSJVergnolleNet al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. (2016) 150:1305–18.e8. 10.1053/j.gastro.2016.02.028
198.
LeeMChangEB. Inflammatory Bowel Diseases (IBD) and the microbiome—searching the crime scene for clues. Gastroenterology. (2021) 160:524–37. 10.1053/j.gastro.2020.09.056
199.
MachielsKJoossensMSabinoJDe PreterVArijsIEeckhautVet al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. (2014) 63:1275–83. 10.1136/gutjnl-2013-304833
200.
ZhouLZhangMWangYDorfmanRGLiuHYuTet al. Faecalibacterium prausnitzii produces butyrate to maintain Th17/treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm Bowel Dis. (2018) 24:1926–40. 10.1093/ibd/izy182
201.
CremonCGuglielmettiSGargariGTavernitiVCastellazziAMValsecchiCet al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: a pilot randomized clinical trial. United Eur Gastroenterol J. (2018) 6:604–13. 10.1177/2050640617736478
202.
FriedrichMPohinMPowrieF. Cytokine networks in the pathophysiology of inflammatory Bowel disease. Immunity. (2019) 50:992–1006. 10.1016/j.immuni.2019.03.017
203.
CocciaMHarrisonOJSchieringCAsquithMJBecherBPowrieFet al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4 + Th17 cells. J Exp Med. (2012) 209:1595–609. 10.1084/jem.20111453
204.
LeeYSYangHYangJYKimYLeeSHKimJHet al. Interleukin-1 (IL-1) signaling in intestinal stromal cells controls KC/ CXCL1 secretion, which correlates with recruitment of IL-22- secreting neutrophils at early stages of Citrobacter rodentium infection. Infect Immun. (2015) 83:3257–67. 10.1128/IAI.00670-15
205.
SongAZhuLGorantlaGBerdyszOAmiciSAGuerau-De-ArellanoMet al. Salient type 1 interleukin 1 receptor expression in peripheral non-immune cells. Sci Rep. (2018) 8:723. 10.1038/s41598-018-19248-7
206.
CoxCBStormEEKapoorVNChavarria-SmithJLinDLWangLet al. IL-1R1-dependent signaling coordinates epithelial regeneration in response to intestinal damage. Sci Immunol. (2021) 6:eabe8856. 10.1126/sciimmunol.abe8856
207.
MadaraJLStaffordJ. Interferon-γ directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest. (1989) 83:724–7. 10.1172/JCI113938
208.
AdamsRBPlanchonSMRocheJK. IFN-gamma modulation of epithelial barrier function. Time course, reversibility, and site of cytokine binding. J Immunol. (1993) 150:2356–63.
209.
SchmitzHFrommMBentzelCJScholzPDetjenKMankertzJet al. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci. (1999) 112(Pt 1):137–46.
210.
BruewerMLuegeringAKucharzikTParkosCAMadaraJLHopkinsAMet al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. (2003) 171:6164–72. 10.4049/jimmunol.171.11.6164
211.
BarbaroMRDi SabatinoACremonCGiuffridaPFiorentinoMAltimariAet al. Interferon-γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. Am J Physiol Gastrointest Liver Physiol. (2016) 310:G439–47. 10.1152/ajpgi.00368.2015
212.
ZolotarevskyYHechtGKoutsourisAGonzalezDEQuanCTomJet al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology. (2002) 123:163–72. 10.1053/gast.2002.34235
213.
BhatAAUppadaSAchkarIWHashemSYadavSKShanmugakonarMet al. Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk. Front Physiol. (2019) 10:1942. 10.3389/fphys.2018.01942
214.
PhamCTN. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. (2006) 6:541–50. 10.1038/nri1841
215.
DaleCVergnolleN. Protease signaling to G protein-coupled receptors: implications for inflammation and pain. J Recept Signal Transduct. (2008) 28:29–37. 10.1080/10799890801941913
216.
ChinACLeeWYNusratAVergnolleNParkosCA. Neutrophil-mediated activation of epithelial protease-activated receptors-1 and−2 regulates barrier function and transepithelial migration. J Immunol. (2008) 181:5702–10. 10.4049/jimmunol.181.8.5702
217.
BarbaraGStanghelliniVDe GiorgioRCorinaldesiR. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil. (2006) 18:6–17. 10.1111/j.1365-2982.2005.00685.x
218.
BashashatiMMoossaviSCremonCBarbaroMRMoravejiSTalmonGet al. Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. (2018) 30:10. 10.1111/nmo.13192
219.
BashashatiMRezaeiNShafieyounAMckernanDPChangLÖhmanLQuigleyEMet al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. (2014) 26:1036–48. 10.1111/nmo.12358
220.
ChangLAdeyemoMKaragiannidisIVidelockEJBoweCShihWet al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol. (2012) 107:262–72. 10.1038/ajg.2011.423
221.
McKernanDPGasznerGQuigleyEMCryanJFDinanTG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther. (2011) 33:1045–52. 10.1111/j.1365-2036.2011.04624.x
222.
DarkohCComerLZewdieGHaroldSSnyderNDuPontHL. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS ONE. (2014) 9:e93144. 10.1371/journal.pone.0093144
223.
WangFGrahamWVWangYWitkowskiEDSchwarzBTTurnerJR. Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. (2005) 166:409–19. 10.1016/S0002-9440(10)62264-X
224.
HanningNEdwinsonALCeuleersHPetersSADe ManJGHassettLCet al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. (2021) 14:1756284821993586. 10.1177/1756284821993586
225.
RengaGMorettiSOikonomouVBorghiMZelanteTPaolicelliGet al. IL-9 and mast cells are key players of Candida albicans commensalism and pathogenesis in the gut. Cell Rep. (2018) 23:1767–78. 10.1016/j.celrep.2018.04.034
226.
GerlachKHwangYNikolaevAAtreyaRDornhoffHSteinerSet al. T H 9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. (2014) 15:676–86. 10.1038/ni.2920
227.
GerlachKMcKenzieANNeurathMFWeigmannB. IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. Tissue Barriers. (2015) 3:e983777. 10.4161/21688370.2014.983777
228.
PicheTBarbaraGAubertPDes VarannesSBDaineseRNanoJLet al. Impaired Intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. (2009) 58:196–201. 10.1136/gut.2007.140806
229.
BarbaraGStanghelliniVDe GiorgioRCremonCCottrellGSSantiniDet al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable Bowel syndrome. Gastroenterology. (2004) 126:693–702. 10.1053/j.gastro.2003.11.055
230.
BarbaraGWangBStanghelliniVde GiorgioRCremonCDi NardoGet al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable Bowel syndrome. Gastroenterology. (2007) 132:26–37. 10.1053/j.gastro.2006.11.039
231.
GecseKRókaRFerrierLLevequeMEutameneHCartierCet al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. (2008) 57:591–8. 10.1136/gut.2007.140210
232.
PontarolloGMannABrandãoIMalinarichFSchöpfMReinhardtC. Protease-activated receptor signaling in intestinal permeability regulation. FEBS J. (2020) 287:645–58. 10.1111/febs.15055
233.
BarbaraGGroverMBercikPCorsettiMGhoshalUCOhmanLet al. Rome foundation working team report on post-infection irritable Bowel syndrome. Gastroenterology. (2019) 156:46–58.e7. 10.1053/j.gastro.2018.07.011
234.
EdogawaSEdwinsonALPetersSAChikkamenahalliLLSundtWGravesSBreen-LylesMJohnsonSDyerRet al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut. (2020) 69:62–73. 10.1136/gutjnl-2018-317416
235.
CenacNBautzovaTLe FaouderPVeldhuisNAPooleDPRollandCet al. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. Gastroenterology. (2015) 149:433–4.e7. 10.1053/j.gastro.2015.04.011
236.
BautzovaTHockleyJRFPerez-BerezoTPujoJTranterMMDesormeauxCet al. 5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein–coupled receptor D. Sci Signal. (2018) 11:eaal2171. 10.1126/scisignal.aal2171
237.
TrifanABurtaOTiucaNPetrisorDCLenghelASantosJ. Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: a randomised, crossover clinical trial. United Eur Gastroenterol J. (2019) 7:1093–101. 10.1177/2050640619862721
238.
Rubio-TapiaAMurrayJA. Updated guidelines by the European Society for the Study of Coeliac Disease. United Eur Gastroenterol J. (2019) 7:581–2. 10.1177/2050640619849370
239.
SchuppanDJunkerYBarisaniD. Celiac disease: from pathogenesis to novel therapies. Gastroenterology. (2009) 137:1912–33. 10.1053/j.gastro.2009.09.008
240.
HarrisLAParkJYVoltaggioLLam-HimlinD. Celiac disease: clinical, endoscopic, and histopathologic review. Gastrointest Endosc. (2012) 76:625–40. 10.1016/j.gie.2012.04.473
241.
GrecoLRominoRCotoIDi CosmoNPercopoSMaglioMet al. The first large population based twin study of coeliac disease. Gut. (2002) 50:624–8. 10.1136/gut.50.5.624
242.
CamineroAMcCarvilleJLGalipeauHJDeraisonCBernierSPConstanteMet al. Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2. Nat Commun. (2019) 10:1–14. 10.1038/s41467-019-09037-9
243.
Di BiaseARMarascoGRavaioliFDajtiEColecchiaLRighiBet al. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study. J Gastroenterol Hepatol. (2020) 36:446–54. 10.1111/jgh.15183
244.
MarascoGCirotaGGRossiniBLungaroLDi BiaseARColecchiaAet al. Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients. Nutrients. (2020) 12:2674. 10.3390/nu12092674
245.
SteneLCHoneymanMCHoffenbergEJHaasJESokolRJEmeryLet al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol. (2006) 101:2333–40. 10.1111/j.1572-0241.2006.00741.x
246.
ZafeiropoulouKNicholsBMackinderMBiskouORizouEKaranikolouAet al. Alterations in intestinal microbiota of children with celiac disease at time of diagnosis and on a gluten-free diet. Gastroenterology. (2020) 159:2039–51.e20. 10.1053/j.gastro.2020.08.007
247.
MarascoGDi BiaseARColecchiaA. Microbial signatures in celiac disease: still far from a final answer. Gastroenterology. (2020) 161:358–9. 10.1053/j.gastro.2020.10.059
248.
MarascoGDi BiaseARSchiumeriniREusebiLHIughettiLRavaioliFet al. Gut microbiota and celiac disease. Dig Dis Sci. (2016) 61:1461–72. 10.1007/s10620-015-4020-2
249.
JabriBAbadieV. IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol. (2015) 15:771–83. 10.1038/nri3919
250.
CatassiCElliLBonazBBoumaGCarroccioACastillejoGet al. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): the Salerno experts' criteria. Nutrients. (2015) 7:4966–77. 10.3390/nu7064966
251.
GiovanniniCSanchezMStrafaceEScazzocchioBSilanoMDe VincenziM. Induction of apoptosis in Caco-2 cells by wheat gliadin peptides. Toxicology. (2000) 145:63–71. 10.1016/S0300-483X(99)00223-1
252.
BaroneMVGimiglianoACastoriaGPaolellaGMauranoFPaparoFet al. Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. Gut. (2007) 56:480–8. 10.1136/gut.2005.086637
253.
HeymanMAbedJLebretonCCerf-BensussanN. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut. (2012) 61:1355–64. 10.1136/gutjnl-2011-300327
254.
ClementeMGDe VirgiliisSKangJSMacatagneyRMusuMPDi PierroMRet al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut. (2003) 52:218–23. 10.1136/gut.52.2.218
255.
AlaediniALatovN. Transglutaminase-independent binding of gliadin to intestinal brush border membrane and GM1 ganglioside. J Neuroimmunol. (2006) 177:167–72. 10.1016/j.jneuroim.2006.04.022
256.
BondarCArayaREGuzmanLRuaECChopitaNChirdoFG. Role of CXCR3/CXCL10 axis in immune cell recruitment into the small intestine in celiac disease. PLoS ONE. (2014) 9:e0089068. 10.1371/journal.pone.0089068
257.
CaredduPChiumelloGVaccariABardareMZilocchiA. Effects of gluten on intestinal absorption and permeability during remission of celiac disease. Boll Soc Ital Biol Sper. (1963) 1963:1235–8.
258.
CobdenIDickinsonRJRothwellJAxonATR. Intestinal permeability assessed by excretion ratios of two molecules: results in coeliac disease. Br Med J. (1978) 2:1060. 10.1136/bmj.2.6144.1060
259.
OberhuberGVogelsangH. Gastrointestinal permeability in celiac disease [1]. Gastroenterology. (1998) 114:226. 10.1016/S0016-5085(98)70661-4
260.
Van ElburgRMUilJJMulderCJJHeymansHSA. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut. (1993) 34:354–7. 10.1136/gut.34.3.354
261.
SchulzkeJDBentzelCJSchulzkeIRieckenEOFrommM. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res. (1998) 43:435–41. 10.1203/00006450-199804000-00001
262.
GoswamiPDasPVermaAKPrakashSDasTKNagTCet al. Are alterations of tight junctions at molecular and ultrastructural level different in duodenal biopsies of patients with celiac disease and Crohn's disease?Virchows Arch. (2014) 465:521–30. 10.1007/s00428-014-1651-1
263.
CiccocioppoRFinamoreAAraCDi SabatinoAMengheriECorazzaGR. Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. Am J Clin Pathol. (2006) 125:502–11. 10.1309/dtyr-a91g-8r0k-tm8m
264.
MontaltoMCuocoLRicciRMaggianoNVecchioFMGasbarriniG. Immunohistochemical analysis of ZO-1 in the duodenal mucosa of patients with untreated and treated celiac disease. Digestion. (2002) 65:227–33. 10.1159/000063817
265.
PerryITselepisCHoylandJIqbalTHScottDSandersAet al. Reduced cadherin/catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab Invest. (1999) 79:1489–99.
266.
SchumannMSiegmundBSchulzkeJDFrommM. Celiac disease: role of the epithelial barrier. CMGH. (2017) 3:150–62. 10.1016/j.jcmgh.2016.12.006
267.
MishraAPrakashSSreenivasVDasTKAhujaVGuptaSDet al. Structural and functional changes in the tight junctions of asymptomatic and serology-negative first-degree relatives of patients with celiac disease. J Clin Gastroenterol. (2016) 50:551–60. 10.1097/MCG.0000000000000436
268.
HuntKAZhernakovaATurnerGHeapGARFrankeLBruinenbergMet al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet. (2008) 40:395–402. 10.1038/ng.102
269.
WapenaarMCMonsuurAJVan BodegravenAAWeersmaRKBevovaMRLinskensRKet al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut. (2008) 57:463–7. 10.1136/gut.2007.133132
270.
MonsuurAJBakkerPIWDAlizadehBZZhernakovaABevovaMRStrengmanEet al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet. (2005) 37:1341–4. 10.1038/ng1680
271.
WoltersVMAlizadehBZWeijermanMEZhernakovaAvan HoogstratenIMWMearinMLet al. Intestinal barrier gene variants may not explain the increased levels of antigliadin antibodies, suggesting other mechanisms than altered permeability. Hum Immunol. (2010) 71:392–6. 10.1016/j.humimm.2010.01.016
272.
KumarVGutierrez-AchuryJKanduriKAlmeidaRHrdlickovaBZhernakovaD Vet al. Systematic annotation of celiac disease loci refines pathological pathways and suggests a genetic explanation for increased interferon-gamma levels. Hum Mol Genet. (2015) 24:397–409. 10.1093/hmg/ddu453
273.
AlmeidaRRicanõ-PonceIKumarVDeelenPSzperlATrynkaGet al. Fine mapping of the celiac disease-associated LPP locus reveals a potential functional variant. Hum Mol Genet. (2014) 23:2481–9. 10.1093/hmg/ddt619
274.
CiccocioppoRPanelliSBellocchiMCCCangemiGCFrulloniLCapelliEet al. The transcriptomic analysis of circulating immune cells in a celiac family unveils further insights into disease pathogenesis. Front Med. (2018) 5:182. 10.3389/fmed.2018.00182
275.
DolfiniERoncoroniLElliLFumagalliCColomboRRamponiSet al. Cytoskeleton reorganization and ultrastructural damage induced by gliadin in a three-dimensional in vitro model. World J Gastroenterol. (2005) 11:7597–601. 10.3748/wjg.v11.i48.7597
276.
StrobelSBrydonWGFergusonA. Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum. Gut. (1984) 25:1241–6. 10.1136/gut.25.11.1241
277.
GassJBethuneMTSiegelMSpencerAKhoslaC. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology. (2007) 133:472–80. 10.1053/j.gastro.2007.05.028
278.
PinierMVerduEFNasser-EddineMDavidCSVézinaARivardNet al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology. (2009) 136:288–98. 10.1053/j.gastro.2008.09.016
279.
PatersonBMLammersKMArrietaMCFasanoAMeddingsJB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. (2007) 26:757–66. 10.1111/j.1365-2036.2007.03413.x
280.
KellyCPGreenPHRMurrayJADimarinoAColatrellaALefflerDAet al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. (2013) 37:252–62. 10.1111/apt.12147
281.
LefflerDAKellyCPAbdallahHZColatrellaAMHarrisLALeonFet al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. (2012) 107:1554–62. 10.1038/ajg.2012.211
282.
LefflerDAKellyCPGreenPHRFedorakRNDimarinoAPerrowWet al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. (2015) 148:1311–9.e6. 10.1053/j.gastro.2015.02.008
283.
HujoelIAMurrayJA. Refractory celiac disease. Curr Gastroenterol Rep. (2020) 22:1–8. 10.1007/s11894-020-0756-8
284.
Jauregi-MiguelA. The tight junction and the epithelial barrier in coeliac disease. Int Rev Cell Mol Biol. (2021) 358:105–32. 10.1016/bs.ircmb.2020.09.010
285.
PearsonADJEasthamEJLakerMFCraftAWNelsonR. Intestinal permeability in children with Crohn's disease and Coeliac disease. Br Med J. (1982) 285:20–21. 10.1136/bmj.285.6334.20
286.
UkabamSOClampJRCooperBT. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion. (1983) 27:70–4. 10.1159/000198932
287.
AbrahamCChoJH. Mechanisms of inflammatory Bowel disease. N Engl J Med. (2009) 361:2066–78. 10.1056/NEJMra0804647
288.
Miner-WilliamsWMMoughanPJ. Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel. Nutr Res Rev. (2016) 29:40–59. 10.1017/S0954422416000019
289.
KhanMWKaleAABerePVajjalaSGounarisEPakanatiKC. Microbes, intestinal inflammation and probiotics. Expert Rev Gastroenterol Hepatol. (2012) 6:81–94. 10.1586/egh.11.94
290.
IngersollSAAyyaduraiSCharaniaMALarouiHYanYMerlinD. The role and pathophysiological relevance of membrane transporter pept1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. (2012) 302:G484–92. 10.1152/ajpgi.00477.2011
291.
DalmassoGNguyenHTTCharrier-HisamuddinLYanYLarouiHDemoulinB.MerlinD. PepT1 mediates transport of the proinflammatory bacterial tripeptide L-Ala-γ-D-Glu-meso-DAP in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. (2010) 299:687–96. 10.1152/ajpgi.00527.2009
292.
JapparDHuYSmithDE. Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice. Drug Metab Dispos. (2011) 39:2250–7. 10.1124/dmd.111.041087
293.
De MedinaFSDaddaouaARequenaPCapitán-CañadasFZarzueloADoloresSuárez Met al. New insights into the immunological effects of food bioactive peptides in animal models of intestinal inflammation. Proc Nutr Soc. (2010) 69:454–62. 10.1017/S0029665110001783
294.
NässlAMRubio-AliagaISailerMDanielH. The intestinal peptide transporter pept1 is involved in food intake regulation in mice fed a high-protein diet. PLoS ONE. (2011) 6:e0026407. 10.1371/journal.pone.0026407
295.
CiprianiSMencarelliAChiniMGDistruttiERengaBBifulcoGet al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE. (2011) 6:e0025637. 10.1371/journal.pone.0025637
296.
Chia-HuiY. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease: RSM Library Discovery Service. J Biomed Sci. (2018) 25:79. 10.1186/s12929-018-0483-8
297.
GruberLLichtiPRathEHallerD. Nutrigenomics and nutrigenetics in inflammatory bowel diseases. J Clin Gastroenterol. (2012) 46:735–47. 10.1097/MCG.0b013e31825ca21a
298.
AnanthakrishnanANBernsteinCNIliopoulosDMacphersonANeurathMFAliRARet al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. (2018) 15:39– 49. 10.1038/nrgastro.2017.136
299.
HoSMLewisJDMayerEAPlevySEChuangERappaportSMet al. Challenges in IBD research: environmental triggers. Inflamm Bowel Dis. (2019) 25:S13–23. 10.1093/ibd/izz076
300.
MahidSSMinorKSSotoREHornungCAGalandiukS. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. (2006) 81:1462–71. 10.4065/81.11.1462
301.
CalkinsBM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. (1989) 34:1841–54. 10.1007/BF01536701
302.
HiguchiLMKhaliliHChanATRichterJMBousvarosAFuchsCS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. (2012) 107:1399–406. 10.1038/ajg.2012.196
303.
PedersenKMÇolakYVedel-KroghSKobyleckiCJBojesenSENordestgaardBG. Risk of ulcerative colitis and Crohn's disease in smokers lacks causal evidence. Eur J Epidemiol. (2021) 10.1007/s10654-021-00763-3. 10.1007/s10654-021-00763-3
304.
SinghUPSinghNPMurphyEAPriceRLFayadRNagarkattiMet al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. (2016) 77:44–9. 10.1016/j.cyto.2015.10.008
305.
OstaffMJStangeEFWehkampJ. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med. (2013) 5:1465–83. 10.1002/emmm.201201773
306.
SalzmanNHHungKHaribhaiDChuHKarlsson-SjöbergJAmirEet al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol. (2010) 11:76–83. 10.1038/ni.1825
307.
Peyrin-BirouletLBeisnerJWangGNudingSOommenSTKellyDet al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA. (2010) 107:8772–7. 10.1073/PNAS.0905745107
308.
WehkampJHarderJWeichenthalMMuellerOHerrlingerKRFellermannKet al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. (2003) 9:215–23. 10.1097/00054725-200307000-00001
309.
MartiniEKrugSMSiegmundBNeurathMFBeckerC. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cmgh. (2017) 4:33–46. 10.1016/j.jcmgh.2017.03.007
310.
CourthLFOstaffMJMailänder-SánchezDMalekNPStangeEFWehkampJ. Crohn's disease-derived monocytes fail to induce Paneth cell defensins. Proc Natl Acad Sci USA. (2015) 112:14000–5. 10.1073/pnas.1510084112
311.
WehkampJKoslowskiMWangGStangeEF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol. (2008) 1:67–74. 10.1038/mi.2008.48
312.
PaonePCaniPD. Mucus barrier, mucins and gut microbiota: the expected slimy partners?Gut. (2020) 69:2232–43. 10.1136/gutjnl-2020-322260
313.
Van Der PostSJabbarKSBirchenoughGArikeLAkhtarNSjovallHet al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut. (2019) 68:2142–51. 10.1136/gutjnl-2018-317571
314.
JohanssonMEAmbortDPelaseyedTSchütteAGustafssonJKErmundAet al. Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci. (2011) 68:3635–41. 10.1007/S00018-011-0822-3
315.
CornickSTawiahAChadeeK. Roles and regulation of the mucus barrier in the gut. Tissue Barriers. (2015) 3:e982426. 10.4161/21688370.2014.982426
316.
Vivinus-NébotMFrin-MathyGBziouecheHDaineseRBernardGAntyRet al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. (2014) 63:744–52. 10.1136/gutjnl-2012-304066
317.
HollanderDVadheimCMBrettholzEPetersonGMDelahuntyTRotterJ. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med. (1986) 105:883–5.
318.
ArnottIDRKingstoneKGhoshS. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol. (2000) 35:1163–9. 10.1080/003655200750056637
319.
WyattJVogelsangHHüblWWaldhoerTLochsH. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. (1993) 341:1437–9. 10.1016/0140-6736(93)90882-H
320.
ArrietaMCBistritzLMeddingsJB. Alterations in intestinal permeability. Gut. (2006) 55:1512–20. 10.1136/gut.2005.085373
321.
MadsenKLMalfairDGrayDDoyleJSJewellLDFedorakRN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis. (1999) 5:262–70. 10.1097/00054725-199911000-00004
322.
ReuterBKPizarroTT. Mechanisms of tight junction dysregulation in the SAMP1YitFc model of Crohn's disease-like ileitis. Ann N Y Acad Sci. (2009) 1165:301–7. 10.1111/j.1749-6632.2009.04035.x
323.
SuLShenLClayburghDRNalleSCSullivanEAJonBet al. Activation and contributes to development of experimental colitis. Gastroenterology. (2010) 136:551–63. 10.1053/j.gastro.2008.10.081
324.
BlairSAKaneS V.ClayburghDRTurnerJR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Investig. (2006) 86:191–201. 10.1038/labinvest.3700373
325.
SwidsinskiALadhoffAPernthalerASwidsinskiSLoening BauckeVOrtnerMet al. Mucosal flora in inflammatory bowel disease. Gastroenterology. (2002) 122:44–54. 10.1053/gast.2002.30294
326.
PrasadSMingrinoRKaukinenKHayesKLPowellRMMacDonaldTTet al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Investig. (2005) 85:1139–62. 10.1038/labinvest.3700316
327.
MénardSCerf-BensussanNHeymanM. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol. (2010) 3:247–59. 10.1038/mi.2010.5
328.
OshimaTLarouxFSCoeLLMoriseZKawachiSBauerPet al. Interferon-γ and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc Res. (2001) 61:130–43. 10.1006/mvre.2000.2288
329.
Albert-BayoMParacuellosIGonzález-CastroAMRodríguez-UrrutiaARodríguez-LagunasMJAlonso-CotonerCet al. Intestinal mucosal mast cells: key modulators of barrier function and homeostasis. Cells. (2019) 8:135. 10.3390/cells8020135
330.
Al-SadiRYeDBoivinMGuoSHashimiMEreifejLet al. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway. PLoS ONE. (2014) 9:e0085345. 10.1371/journal.pone.0085345
331.
GasslerNRohrCSchneiderAKartenbeckJBachAObermüllerNet al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol. (2001) 281:216–28. 10.1152/ajpgi.2001.281.1.g216
332.
ShihDQMichelsenKSBarrettRJBiener-RamanujanEGonskyRZhangXet al. Insights into TL1A and IBD pathogenesis. Adv Exp Med Biol. (2011) 691:279–88. 10.1007/978-1-4419-6612-4_29
333.
CooneyRJewellD. The genetic basis of inflammatory bowel disease. Dig Dis. (2009) 27:428–42. 10.1159/000234909
334.
IshiharaSAzizMMYukiTKazumoriHKinoshitaY. Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol. (2009) 44:1097–108. 10.1007/s00535-009-0141-8
335.
MayerL. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. (2010) 45:9–16. 10.1007/s00535-009-0138-3
336.
HugotJPChamaillardMZoualiHLesageSCézardJPBelaicheJet al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. (2001) 411:599–603. 10.1038/35079107
337.
KosovacKBrenmoehlJHollerEFalkWSchoelmerichJHausmannMet al. Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflamm Bowel Dis. (2010) 16:1311–21. 10.1002/ibd.21223
338.
RosenstielPSebreiberS. NOD-like receptors-pivotal guardians of the immunological integrity of barrier organs. Adv Exp Med Biol. (2009) 653:35–47. 10.1007/978-1-4419-0901-5_3
339.
GirardinSEBonecaIGVialaJChamaillardMLabigneAThomasGet al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. (2003) 278:8869–72. 10.1074/jbc.C200651200
340.
InoharaNOguraYFontalbaAGutierrezOPonsFCrespoJet al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem. (2003) 278:5509–12. 10.1074/jbc.C200673200
341.
RosenstielPFantiniMBräutigamKKühbacherTWaetzigGHSeegertDet al. TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology. (2003) 124:1001–9. 10.1053/gast.2003.50157
342.
BuhnerSBuningCGenschelJKlingKHerrmannDDignassAet al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?Gut. (2006) 55:342–7. 10.1136/gut.2005.065557
343.
MatsuokaKKanaiT. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. (2015) 37:47–55. 10.1007/s00281-014-0454-4
344.
FukataMArditiM. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol. (2013) 6:451–63. 10.1038/mi.2013.13
345.
ZeuthenLHFinkLNFrokiaerH. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-β. Immunology. (2008) 123:197–208. 10.1111/j.1365-2567.2007.02687.x
346.
RimoldiMChieppaMSalucciVAvogadriFSonzogniASampietroGMet al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol. (2005) 6:507–14. 10.1038/ni1192
347.
TravisSMenziesI. Intestinal permeability: functional assessment and significance. Clin Sci. (1992) 82:471–88. 10.1042/cs0820471
348.
BjarnasonIMacphersonAHollanderD. Intestinal permeability: an overview. Gastroenterology. (1995) 108:1566–81. 10.1016/0016-5085(95)90708-4
349.
WehkampJStangeEF. Paneth's disease. J Crohn's Colitis. (2010) 4:523–31. 10.1016/j.crohns.2010.05.010
350.
KhoshbinKCamilleriM. Effects of dietary components on intestinal permeability in health and disease. Am J Physiol Gastrointest Liver Physiol. (2020) 319:G589–608. 10.1152/AJPGI.00245.2020
351.
CamilleriM. Human intestinal barrier: effects of stressors, diet, prebiotics, and probiotics. Clin Transl Gastroenterol. (2021) 12:e00308. 10.14309/ctg.0000000000000308
352.
KlimbergVSSoubaWW. The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness. Surg Annu. (1990) 22:61–76.
353.
ZhouYPJiangZMSunYHWangXRMaELWilmoreD. The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. J Parenter Enter Nutr. (2003) 27:241–5. 10.1177/0148607103027004241
354.
PengXYanHYouZWangPWangS. Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients. Burns. (2004) 30:135–9. 10.1016/j.burns.2003.09.032
355.
ZhouQQVerneMLFieldsJZLefanteJJBasraSSalamehHet al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. (2019) 68:996–1002. 10.1136/gutjnl-2017-315136
356.
NormanAW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. (2008) 88:491–9S. 10.1093/ajcn/88.2.491s
357.
KongJZhangZMuschMWNingGSunJHartJet al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. (2007) 294:G208–16. 10.1152/ajpgi.00398.2007
358.
HewisonM. Vitamin D and innate and adaptive immunity. Vitam Horm. (2011) 86:23–62. 10.1016/B978-0-12-386960-9.00002-2
359.
FroicuMCantornaMT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. (2007) 8:5. 10.1186/1471-2172-8-5
360.
ZhaoHZhangHWuHLiHLiuLGuoJet al. Protective role of 1,25(OH)2vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. (2012) 12:57. 10.1186/1471-230X-12-57
361.
Guzman-PradoYSamsonOSegalJPLimdiJKHayeeB. Vitamin D therapy in adults with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. (2020) 26:1819–30. 10.1093/ibd/izaa087
362.
RafteryTMartineauARGreillerCLGhoshSMcNamaraDBennettKet al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: results from a randomised double-blind placebo-controlled study. United Eur Gastroenterol J. (2015) 3:294–302. 10.1177/2050640615572176
363.
Corrêa-OliveiraRFachiJLVieiraASatoFTVinoloMAR. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. (2016) 5:e73. 10.1038/cti.2016.17
364.
Ríos-CoviánDRuas-MadiedoPMargollesAGueimondeMDelos Reyes-Gavilán CGSalazarN. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. (2016) 7:185. 10.3389/fmicb.2016.00185
365.
BarcenillaAPrydeSEMartinJCDuncanSHStewartCSHendersonCet al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. (2000) 66:1654–61. 10.1128/AEM.66.4.1654-1661.2000
366.
LouisPYoungPHoltropGFlintHJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol. (2010) 12:304–14. 10.1111/j.1462-2920.2009.02066.x
367.
VitalMHoweACTiedjeJM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. (2014) 5:e00889. 10.1128/mBio.00889-14
368.
KannampalliPShakerRSenguptaJN. Colonic butyrate- algesic or analgesic?Neurogastroenterol Motil. (2011) 23:975–9. 10.1111/j.1365-2982.2011.01775.x
369.
BanasiewiczTKrokowiczStojcevZKaczmarekBFKaczmarekEMaikJet al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Color Dis. (2013) 15:204–9. 10.1111/j.1463-1318.2012.03152.x
Summary
Keywords
intestinal epithelial barrier, mucosal immune system, gut microbiota, IBS, IBD, celiac disease, non-celiac gluten sensitivity
Citation
Barbara G, Barbaro MR, Fuschi D, Palombo M, Falangone F, Cremon C, Marasco G and Stanghellini V (2021) Corrigendum: Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Front. Nutr. 8:790387. doi: 10.3389/fnut.2021.790387
Received
06 October 2021
Accepted
07 October 2021
Published
01 November 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
8 - 2021
Updates
Copyright
© 2021 Barbara, Barbaro, Fuschi, Palombo, Falangone, Cremon, Marasco and Stanghellini.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giovanni Barbara giovanni.barbara@unibo.it
This article was submitted to Nutritional Immunology, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.